Objective:
To address concerns regarding the limited availability of joint scientific consultation (JSC) meetings impacting Joint Clinical Assessments (JCAs) for cancer and gene therapies under the EU Health Technology Assessment (HTA) Regulation.
Approach:
- Stakeholder Concerns: EU-based pharmaceutical innovators express concerns over the insufficient number of JSC meetings, which could hinder the execution of JCAs.
- Regulatory Context: The HTA Regulation, effective January 12, 2025, aims to standardize health technology assessments across EU member states.
- Industry Response: Industry associations, including EFPIA, call for increased JSC meetings and collaboration between regulatory bodies and the pharmaceutical industry.
Key Findings:
- Only 5 to 7 JSC meetings are planned for 2025, insufficient for the expected demand.
- The number of planned JSCs is less than a third of the anticipated JCAs for 2025.
- Insufficient early dialogue on trial designs may compromise the quality and timeliness of JCAs.
Interpretation:
Limitations:
- The forecasted number of JSC meetings does not align with the realities of product development.
- The complexity of harmonizing regulations across the EU may complicate clinical trial design and implementation.
Conclusion:
Sources:
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.
